The MRC OV05/EORTC 55,955 trial investigated early vs. delayed treatment based on CA125 PD in 1442 patients with ovarian cancer in remission with unelevated CA125 values after adjuvant platinum-based chemotherapy24. Here, MUC16 is linked to ovarian carcinoma.